Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily

Xenobiotica

Volumn 29, Issue 9, 1999, Pages 931-944

  Gorski, J C ^a,c   Jones, D R ^a   Hamman, M A ^a   Wrighton, S A ^b   Hall, S D ^a  

^a INDIANA UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DRUG METABOLITE; ERYTHROMYCIN; MIDAZOLAM; OXYGENASE; TROLEANDOMYCIN;

ARTICLE; B LYMPHOBLAST; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM;

ALPRAZOLAM; ARYL HYDROCARBON HYDROXYLASES; B-LYMPHOCYTES; BENZOFLAVONES; BIOTRANSFORMATION; COUMARINS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYPNOTICS AND SEDATIVES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; QUINIDINE; RECOMBINANT PROTEINS; SULFAPHENAZOLE; TROLEANDOMYCIN;

EID: 0032829243     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238173     Document Type: Article

References (53)

1. ABERNETHY, D. R., GREENBLATT, D. J., MORSE, D.S. and SHADER, R. I., 1985, Interaction of propoxyphene with diazepam, alprazolam, and lorazepam. British Journal of Clinical Pharmacology, 19, 51-57.
2. ALLONEN, H., ZIEGLER, G. and KLOTZ, U., 1981, Midazolam kinetics. Clinical Pharmacology and Therapeutics, 30, 653-660.
3. ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131-137.
4. AOYAMI, T., YAMANO, S., WAXMAN, D. J., LAPENSON, D. P., MEYER, U. A., FISCHER, V., TYNDALE, R., INABA, T., KALOW, W., GELBOIN, H. V. and GONZALEZ, F. J., 1989, Cytochrome P450 HPCN3, a novel cycochrome P-450 IIIA gene product that is differentially expressed in adult liver. Journal of Biological Chemistry, 264, 13095-10395.
5. CIRAULO, D. A., BARNHILL, J. G., BOXENBAUM, H. G., GREENBLATT, D. J. AND SMITH, R. B., 1986, Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. Journal of Clinical Pharmacology, 26, 292-298.
6. CRESPI, C. L., CODE, E. L., PENMAN, B. W. and WAXMAN, D. J., 1995, An activity-based method for integrating metabolism data from cDNA-expressed cytochrome P450 enzymes to the balance of enzymes in human liver microsomes. ISSX Proceedings, 8, 420-
7. FLEISHAKER, J. C. and HULST, L. K., 1994, A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. European Journal of Clinical Pharmacology, 46, 35-39.
8. FRIEDMAN, H., REDMOND, D. E. JR. and GREENBLATT, D. J., 1991, Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. Psychopharmacology, 104, 103-105.
9. GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. and WRIGHTON, S. A. 1994a, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643-1653.
10. GORSKI, J. C., JONES, D. R., WRIGHTON, S. A. and HALL, S. D., 1994b, Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 48, 173-182.
11. GORSKI, J. C., JONES, D. R., WRIGHTON, S. A. and HALL, S. D., 1997, Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica, 27, 243-256.
12. GORSKI, J. C., JONES, D. R., HAEHNER-DANIELS, B. D., HAMMAN, M. A., O'MARA, E. M. and HALL, S. D., 1998, The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clinical Pharmacology and Therapeutics, 64, 133-143.
13. GREENBLATT, D. J., PRESKORN, S. H., COTREAU, M. M., HORST, W. D. and HARMATZ, J. S., 1992, Fluoxetine impairs the clearance of alprazolam but not of clonazepam. Clinical Pharmacology and Therapeutics, 52, 479-486.
14. GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., CIRAULO, D. A. and SHADER, R. I., 1993, Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Journal of Clinical Psychiatry, 54, 4-11.
15. GREENBLATT, D. J. and WHIGHT, C. E., 1993, Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clinical Pharmacokinetics, 24, 453-471.
16. GHEENBLATT, D. J., WHIGHT, C. E., VON MOLTKE, L. L., HARMATZ, J. S., EHRENBERG, B. L., HARREL, L. M., CORBETT, K., COUNIHAN, M., TOBIAS, S. and SHADER, R. I., 1998, Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clinical Pharmacology & Therapeutics, 64, 237-247.
17. GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T. and WAXMAN, D. J., 1986, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a protype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 5051-5060.
18. GUENGERICH, F. P., BRIAN, W. R., IWASAKI, M., SARI, M.-A., BÄÄRNHIELM, C. and BERNTSSON, P., 1991, Oxidation of dihydropyridine calcium channel blocker analogues by human liver cytochrome P450IIIA4. Journal of Medical Chemistry, 34, 1838-1844.
19. HALL, S. D., HAMMAN, M. A., RETTIE, A. E., WIENKERS, L. C., TRACER, W. F., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994, Relationship between the levels of cytochrome P450 2C9 and itsprototypic catalytic activities in human liver microsomes. Drug Metabolism and Disposition, 22, 975-978.
20. HEBERT, M. F., ROBERTS, J. P., PRUEKSARITANONT, T. and BENET, L. Z., 1992, Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clinical Pharmacology and Therapeutics, 52, 453-457.
21. HONIG, P. K., WOOSLEY, R. L., ZAMANI, K., CONNER, D. P. and CANTILENA, L. R., 1992, Changes in the pharmacokinctics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of crythromycin. Clinical Pharmacology and Therapeutics, 52, 231-238.
22. KERR, B. M., THUMMEL, K. E., WURBEN, C. J., KLEIN, S. M., KROETZ, D. L., GONZALEZ, F. J. and LEVY, R. H., 1994, Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical Pharmacology, 47, 1969-1979.
23. KERLAN, V., DREANO, Y., BEHCOVICI, J. P., BEAUNE, P. H., FLOCH, H. H. and BERTHOU, F., 1992, Nature of cytochromes P450 involved in the 2-/4-hydroxylation of estradiol in human liver microsomes. Biochemical Pharmacology, 44, 1745-1756.
24. KROBOTH, P. D., SMITH, R. B., STOEHR, G. P. and JUHL, R. P., 1985, Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clinical Pharmacology and Therapeutics, 38, 525-532.
25. KRONBACH, T., FISCHER, V. and MEYER, U. A., 1988, Cyclosporine metabolism in human liver: Identification of cytochrome P-450III gene family as the major cyclosporme-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics, 43, 630-635.
26. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F.J. and MEYER, U.A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89-96.
27. LASHER, T. A., FLEISHAKER, J. C., STEENWIK, R. C. and ANTAL., E. J., 1991, Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolamand fluoxetine. Psychopharmacology, 104, 323-327.
28. LOWRY, O. R., ROSEBROUGH, J. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
29. NEWTON, D. J., WANG, R.W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
30. OLKKOLA, K. T., ARANKO, K., LUURILA, H., HILLER, A., SAARNIVAARA, L., HIMBERG, J.-J. and NEUVONEN, P. J., 1993, A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 53, 298-305.
31. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemeprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
32. SCHMIDER, J., GREENBLATT, D. J., VON MOLTKE, L. L., HARMATZ, J. S., DUAN, S. X., KARSOV, D. and SHADER, R. I., 1996, Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology, 52, 125-134.
33. SCHWAB, G. E., RAUCY, J. L., and JOHNSON, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Molecular Pharmacology, 33, 493-499.
34. SHIMADA, T., YAMAZAKI, H., MIMUKA, M., INUI, Y. and GUENGERICH, F. P., 1994, Inter-individual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasions. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
35. SHOU, M., GROGAN, J., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEKWA, K. R., 1994, Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrorne P450 active site. Biochemistry, 33, 6450-6455.
36. SMITH, R. B., KROBOTH, P. D., VANDERLUGT, J. T., PHILLIPS, J. P. and JUHL, R. P., 1984, Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology, 84, 452-456.
37. SOKAL, R. R. and ROHLF, F. J., 1981, Biometry, 2nd edn (New York: W. H. Freeman).
38. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E.,McMANUS, M. E., TUKEY, R. H., QUARTTROCHI, L. C., GELBOIN, H. V. and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
39. VANDER HOEVEN, T. A. and COON, M. J., 1974, Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. Journal of Biological Chemistry, 249, 6302-6310.
40. VENKATAKRISHNAN, K., GREENBLATT, D. J., VON MOLTKE, R. I., and SHADER, R. I., 1998, Alprazolam is another substrate for human cytochrome P450-3A isoforms. Journal of Clinical Psychopharmacology, 18, 256.
41. VINCENT, S. H., KARANAM, B. V., PAINTER, S. K. and CHUI, S.-H., 1992, In vitro metabolism of FK-506 in rat, rabbit and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as a major enzymes responsible for its metabolism. Archives in Biophysics, 294, 454-460.
42. VON MOLTKE, L. L., GHEENBLATT, D. J., COTREAU-BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole, and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
43. VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S. and SHADEH, R. I., 1993, Alprazolam metabolism in vitro: studies of human, monkey mouse and rat liver microsomes. Pharmacology, 47, 268-276.
44. WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETA, E. G., MENDES-PICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P450 in human liver. Proceedings of the National Academy of Sciences, USA, 82, 6310-6314.
45. WRIGHTON, S. A., BRIAN, W. R., SARI, M.-A., IWASAKI, M., GUENGERICK, F. P., RAUCY, J. L., MOLOWA, D. T. and VANDENBRANDEN, M., 1990, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HIp3). Molecular Pharmacology, 38, 207-213.
46. WRIGHTON, S. A., MAUREL, P., SCHEUTZ, E. G., WATKINS, P. B., YOUNG, B. and GUZELIAN, P. S., 1985, Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry, 25, 2171-2178.
47. WRIGHTON, S. A., RING, B. J., WATKINS, P. B. and VANDEN BRANDEN, M., 1989, Identification of a polymorphically expressed member of the human cytochrome P-450III family. Molecular Pharmacology, 36, 97-105.
48. WRIGHTON, S.A., STEVENS, J. C., BECKER, G. W. and VANDENBRANDEN, M., 1993a, Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Archives in Biochemistry and Biophysics, 306, 240-245.
49. WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTIE, A. E. and CASHMAN, J. R., 1993b, In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Review, 25, 453-484.
50. WU, C. Y., BENET, L. Z., HEBERT, M. F., GUPTA, S. K., ROWLAND, M., GOMEZ, D. Y. and WACHER, V. J., 1995, Differtiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clinical Pharmacology & Therapeutics, 58, 492-497.
51. YASUI, N., OTANI, K., KANEKO, S., OHKUBO, T., OSANAI, T., SUGAWARA, K., CHIBA, K. and ISHIZAKI, T., 1996, A kinetic and dynamic study of ral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clinical Pharmacology and Therapeutics, 59, 514-519.
52. YUN, C.-H., OKERHOLM, R. A. and GUEKGERICH, F. P., 1993, Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P4503A(4) in N-dealkylation and C-hydroxylation. Drug Metabolism and Disposition, 21, 403-409.
53. ZHOU, X.-J., ZHOC-PAM, X.-R., GAUTHIER, T., PLACIDI, M., MAUREL, R. and RAHMANI, R., 1993, Human liver microsomal cytochrome P450 3A jsozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochemical Pharmacology, 45, 853-861.